CT
Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
71.60 zł -1.51% (-1.10 zł)
1M +4.01%
Market Cap 460.4M zł
P/E Ratio -
Div. Yield -
ROE 150.18%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 38.20x
P/S 193.30x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 37.53%
Rev. growth 20.16%
FCF growth N/A
Profitability
16 /100
Weak Net margin 1,790.64%
Op. margin 1,973.80%
FCF margin 3,030.69%
Quality
1 /100
Poor ROE 150.18%
ROA 163.44%
Asset turnover 0.09x
Debt
65 /100
Moderate Current ratio 1.60x
Int. coverage -181.05x
Debt/Equity 0.26x
Stability
29 /100
Unstable Rev. volatility 60.45%
EPS volatility 62.50%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CTX.WA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michal Jerzy Walczak
Employees
82
Headquarters
Wroclaw
Nadcházející události
02 PRO
Earnings
Upcoming earnings report